MX379649B - Derivados de azetidina para formacion de imágenes de tau. - Google Patents
Derivados de azetidina para formacion de imágenes de tau.Info
- Publication number
- MX379649B MX379649B MX2018005376A MX2018005376A MX379649B MX 379649 B MX379649 B MX 379649B MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 379649 B MX379649 B MX 379649B
- Authority
- MX
- Mexico
- Prior art keywords
- tau imaging
- azetidine derivatives
- tau
- imaging
- compound
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical class C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0444—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un nuevo compuesto de la fórmula: métodos de preparación de este compuesto, métodos de uso de este compuesto para imágenes tau y preparaciones de formulaciones de formación de imágenes de tau.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254906P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/060621 WO2017083198A1 (en) | 2015-11-13 | 2016-11-04 | Azetidine derivatives for tau imaging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005376A MX2018005376A (es) | 2018-08-01 |
| MX379649B true MX379649B (es) | 2025-03-11 |
Family
ID=57389526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005376A MX379649B (es) | 2015-11-13 | 2016-11-04 | Derivados de azetidina para formacion de imágenes de tau. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10301308B2 (es) |
| EP (1) | EP3374358B1 (es) |
| JP (1) | JP2018531978A (es) |
| KR (1) | KR20180061364A (es) |
| CN (1) | CN108290883B (es) |
| AU (1) | AU2016351609B2 (es) |
| BR (1) | BR112018006969B1 (es) |
| CA (1) | CA3003884C (es) |
| DK (1) | DK3374358T3 (es) |
| EA (1) | EA034018B1 (es) |
| ES (1) | ES2864825T3 (es) |
| IL (1) | IL258313B (es) |
| MX (1) | MX379649B (es) |
| PL (1) | PL3374358T3 (es) |
| PT (1) | PT3374358T (es) |
| SA (1) | SA518391527B1 (es) |
| WO (1) | WO2017083198A1 (es) |
| ZA (1) | ZA201802526B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240145486A (ko) * | 2022-02-03 | 2024-10-07 | 일라이 릴리 앤드 캄파니 | 알츠하이머병을 진단 및 치료하기 위한 국소 타우 영상화 |
| AU2024214741A1 (en) * | 2023-02-02 | 2025-08-21 | Eli Lilly And Company | Novel compounds for tau imaging |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004054978A1 (ja) * | 2002-12-16 | 2006-04-20 | 株式会社 ビーエフ研究所 | タウ蛋白蓄積性疾患の診断プローブとしてのキノリン誘導体 |
| US8318132B2 (en) | 2008-02-14 | 2012-11-27 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological dysfunction |
| NZ593848A (en) * | 2008-12-31 | 2013-09-27 | Avid Radiopharmaceuticals Inc | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| CN107011342A (zh) | 2012-05-22 | 2017-08-04 | 伊莱利利公司 | 用于检测神经功能障碍的基于咔啉和咔唑的成像剂 |
-
2016
- 2016-11-04 US US15/763,608 patent/US10301308B2/en active Active
- 2016-11-04 KR KR1020187013117A patent/KR20180061364A/ko not_active Withdrawn
- 2016-11-04 CA CA3003884A patent/CA3003884C/en active Active
- 2016-11-04 PT PT167988740T patent/PT3374358T/pt unknown
- 2016-11-04 ES ES16798874T patent/ES2864825T3/es active Active
- 2016-11-04 CN CN201680066210.8A patent/CN108290883B/zh active Active
- 2016-11-04 PL PL16798874T patent/PL3374358T3/pl unknown
- 2016-11-04 EA EA201890799A patent/EA034018B1/ru not_active IP Right Cessation
- 2016-11-04 DK DK16798874.0T patent/DK3374358T3/da active
- 2016-11-04 AU AU2016351609A patent/AU2016351609B2/en active Active
- 2016-11-04 WO PCT/US2016/060621 patent/WO2017083198A1/en not_active Ceased
- 2016-11-04 MX MX2018005376A patent/MX379649B/es unknown
- 2016-11-04 BR BR112018006969-8A patent/BR112018006969B1/pt not_active IP Right Cessation
- 2016-11-04 EP EP16798874.0A patent/EP3374358B1/en active Active
- 2016-11-04 JP JP2018522120A patent/JP2018531978A/ja not_active Withdrawn
-
2018
- 2018-03-22 IL IL258313A patent/IL258313B/en active IP Right Grant
- 2018-04-17 ZA ZA201802526A patent/ZA201802526B/en unknown
- 2018-05-07 SA SA518391527A patent/SA518391527B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA034018B1 (ru) | 2019-12-19 |
| US10301308B2 (en) | 2019-05-28 |
| IL258313B (en) | 2021-04-29 |
| EA201890799A1 (ru) | 2018-10-31 |
| HK1257042A1 (zh) | 2019-10-11 |
| AU2016351609B2 (en) | 2019-08-08 |
| BR112018006969A2 (en) | 2018-10-16 |
| WO2017083198A1 (en) | 2017-05-18 |
| PT3374358T (pt) | 2021-03-31 |
| EP3374358B1 (en) | 2021-02-17 |
| US20180282322A1 (en) | 2018-10-04 |
| SA518391527B1 (ar) | 2021-02-07 |
| EP3374358A1 (en) | 2018-09-19 |
| ZA201802526B (en) | 2019-10-30 |
| BR112018006969B1 (pt) | 2022-04-26 |
| MX2018005376A (es) | 2018-08-01 |
| CN108290883A (zh) | 2018-07-17 |
| PL3374358T3 (pl) | 2021-07-12 |
| CN108290883B (zh) | 2021-02-09 |
| CA3003884A1 (en) | 2017-05-18 |
| JP2018531978A (ja) | 2018-11-01 |
| AU2016351609A1 (en) | 2018-04-19 |
| KR20180061364A (ko) | 2018-06-07 |
| ES2864825T3 (es) | 2021-10-14 |
| CA3003884C (en) | 2020-04-21 |
| IL258313A (en) | 2018-05-31 |
| DK3374358T3 (da) | 2021-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132627A2 (es) | Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| PH12018500457A1 (en) | New phenoxymethyl derivatives | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| EP4279071A3 (en) | Novel cannabinoid formulations | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| PH12018500591B1 (en) | Heterocyclic compounds and uses thereof | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| CY1121746T1 (el) | Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης | |
| EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA201790570A1 (ru) | Модуляторы р2х7 | |
| EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201792000A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| EA201790275A1 (ru) | Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида | |
| EA201792262A1 (ru) | Пироглутамат вортиоксетина | |
| EA201992360A1 (ru) | Кристаллические формы (s)-афоксоланера | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| EP3682016A4 (en) | FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS | |
| BR112017019176A2 (pt) | processos para a preparação de fluorocetolídeos | |
| MX2016003725A (es) | Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau. |